KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025.New Obesity, Metabolic & Inflammatory Disease ...
Researchers have identified new roles for a protein long known to protect against severe flu infection – among them, raising the minimum number of viral particles needed to cause sickness.